AC Nova Technologies Inc. (ATI Pharma) Announces the USA and Canada Launch of NutraPause

Share Article

NutraPause is a Botanical Supplement Clinically Shown to Significantly Relieve Vasomotor Symptoms (Hot Flashes and Night Sweats) Associated with Peri Menopause and Menopause

“The approval of NutraPause presents an exciting opportunity for women."said Carmella Angus, Founder and Chairman of the Board of ATI Pharma.

AC Nova Technologies Inc (aka “ATI Pharma”) announces the USA and Canada Launch of NutraPause, a botanical supplement clinically shown to significantly relieve Vasomotor Symptoms (Hot Flashes and Night Sweats) Associated with Peri Menopause and Menopause.

AC Nova Technologies Inc (aka ATI Pharma), a leader in the development of evidence-based botanical supplements, is pleased to announce that Health Canada has approved NutraPause for the treatment of vasomotor symptoms associated with perimenopause and menopause. Menopause is a normal, natural event that marks the permanent end of fertility. There are an estimated 18 million women aged 45-59 in North America who suffer some symptoms of menopause every year including hot flashes and night sweats. For decades, doctors have treated these symptoms using an antiquated and dangerous model called Hormone Replacement Therapy (HRT).
In 2002, findings from a large clinical study known as the Women’s Health Initiative, raised significant concerns about the long-term safety of traditional HRT treatment. This has led to a concerted effort for therapies that do not increase those risks identified to be associated with traditional HRT. NutraPause`s active ingredients have been demonstrated through a double-blind placebo controlled clinical study (Garcia et al 2010) to be both effective and safe in alleviating vasomotor symptoms. This Phase III clinical trial showed a significant decrease in the weekly number of vasomotor symptoms, most notably hot flashes and night sweats by half. Safety data reiterates that these active ingredients are well tolerated with no significant adverse events in the treatment group versus placebo.

This may be the first clinical study to have shown clinically significant efficacy in reducing vasomotor symptoms using alternative herbal therapies, contained in NutraPause. “The approval of NutraPause presents an exciting opportunity for women and their doctors and/or other healthcare practitioners to discuss a new and novel evidence-based alternative, effective and safe treatment option for managing hot flashes and night sweats,” said Carmella Angus, Founder and Chairman of the Board of ATI Pharma.

At AC Nova Technologies Inc (ATI Pharma), we strive to bring to the public only evidence-based natural therapies that have been clinically shown to improve quality of life and/or delay the onset of a medical condition. We strive to set the standard for quality, safety and value in the licensing, development and manufacture of health care products. As with all nutritional supplements, if you are suffering from a medical condition, please consult your healthcare professional before use. This product should not be used by women who are pregnant or lactating.

AC Nova Technologies Inc is the exclusive licensee of a patented platform technology developed by the University of Singapore (NUS). One of the key components in NutraPause has been shown by Scientists at NUS to modulate both the estrogen and androgen receptors, in vivo and in vitro. It is believed that this may be the mechanism of action responsible for NutraPause alleviating vasomotor symptoms such as hot flashes and night sweats. ATI Pharma will be conducting additional clinical studies to evaluate this technology’s efficacy on other symptoms which might be associated with its modulatory action on the estrogen and androgen receptor.

AC Nova Technologies is also pleased to announce that it has signed an exclusive distribution agreement (For Canada Only) with a well-established distributor located in Canada, TFB &Associates Limited Markham Ontario. ATI Pharma anticipates that NutraPause will be available in Canada and the USA in the early First Quarter of 2014. To learn more about the product, indications approved by Health Canada or potential investment, sales or distribution opportunities, please visit us at or contact Keith Larson, President, AC Nova Technologies Inc at larsonskl(at)comcast(dot)net or 303-523-2468.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Keith Larson
Visit website